UK drug firm may have provided incomplete view of efficacy data from US trial, says safety monitor
AstraZeneca may have provided an incomplete view of efficacy data on its Covid-19 vaccine from a large-scale trial in the United States, a US health agency has said, in a fresh setback for the drug.
The concerns throw into question whether the British pharmaceutical firm can seek US emergency use authorisation for the vaccine in the coming weeks as planned, and come just one day after interim data from the trial had shown better-than-expected results.
Continue reading...Know the benifits of facebook marketing ---http://bit.ly/2RgChw3
0 Comments